Literature DB >> 34398670

Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.

Christian M Gill1, Elif Aktaş2, Wadha Alfouzan3,4, Lori Bourassa5, Adrian Brink6, Carey-Ann D Burnham7, Rafael Canton8, Yehuda Carmeli9, Marco Falcone10, Carlos Kiffer11, Anna Marchese12,13, Octavio Martinez14, Spyros Pournaras15, Harald Seifert16, Abrar K Thabit17, Maria Virginia Villegas18, Lars F Westblade19, David P Nicolau1,20.   

Abstract

The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.

Entities:  

Keywords:  Pseudomonas aeruginosa; carbapenem resistance; cefepime; ceftazidime; pharmacodynamics; pharmacokinetics

Mesh：

Substances：

Year:  2021        PMID： 34398670      PMCID： PMC8522773          DOI： 10.1128/AAC.01204-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.

Authors:  Emily L Heil; J Kristie Johnson
Journal:  J Clin Microbiol       Date:  2016-01-20       Impact factor: 5.948

Review 2.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

3.  Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

Authors:  Vincent H Tam; Kai-Tai Chang; Jian Zhou; Kimberly R Ledesma; Kady Phe; Song Gao; Françoise Van Bambeke; Ana María Sánchez-Díaz; Laura Zamorano; Antonio Oliver; Rafael Cantón
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

Review 4.  The Genotype-to-Phenotype Dilemma: How Should Laboratories Approach Discordant Susceptibility Results?

Authors:  Rebecca Yee; Jennifer Dien Bard; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2021-05-19       Impact factor: 5.948

5.  Intermittent bolus dosing of ceftazidime in critically ill patients.

Authors:  R J Young; J Lipman; T Gin; C D Gomersall; G M Joynt; T E Oh
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

6.  Impact of revised cefepime CLSI breakpoints on Escherichia coli and Klebsiella pneumoniae susceptibility and potential impact if applied to Pseudomonas aeruginosa.

Authors:  Yukihiro Hamada; Christina A Sutherland; David P Nicolau
Journal:  J Clin Microbiol       Date:  2015-02-18       Impact factor: 5.948

7.  Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.

Authors:  Vincent H Tam; Peggy S McKinnon; Ronda L Akins; George L Drusano; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

8.  Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Authors:  Nathaniel J Rhodes; Joseph L Kuti; David P Nicolau; Scott Van Wart; Anthony M Nicasio; Jiajun Liu; Benjamin J Lee; Michael N Neely; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

9.  Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Catharine C Bulik; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

10.  The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Christian M Gill; Elif Aktaþ; Wadha Alfouzan; Lori Bourassa; Adrian Brink; Carey-Ann D Burnham; Rafael Canton; Yehuda Carmeli; Marco Falcone; Carlos Kiffer; Anna Marchese; Octavio Martinez; Spyros Pournaras; Michael Satlin; Harald Seifert; Abrar K Thabit; Kenneth S Thomson; Maria Virginia Villegas; David P Nicolau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-07-22       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.